Developing new drugs that target a specific form of a cancer-related protein.
Official title: Targeting Oxidized PTP1B for Anticancer Drug Discovery
Funded at Florida Atlantic University · NIH-11046669 · Data updated 2026-11-12
This study is looking at a protein called PTP1B that is often found in higher levels in cancer cells, and the researchers want to create new drugs that can specifically target this protein to help improve cancer treatments for patients.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida Atlantic University NIH-funded |
| Lab location | 1 site (Boca Raton, United States) |
| Project start | September 1, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $76,250 |
| NIH project number | 5R03CA289646-03 |
| Project ID | NIH-11046669 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancers that exhibit high levels of PTP1B, such as breast cancer.
✕Less likely to help
Patients with cancers that do not involve PTP1B or those who are not eligible for new drug trials may not benefit from this research.
What this research studies
This research focuses on a protein called PTP1B, which is often found in higher amounts in various cancers and is linked to poor patient outcomes. The team aims to create new drugs that specifically target the oxidized form of PTP1B, which is more prevalent in cancerous cells. By developing inhibitors that can effectively interact with this oxidized protein, the research seeks to improve drug selectivity and bioavailability. The approach includes preparing and screening a variety of chemical compounds to find those that can successfully bind to and stabilize the oxidized PTP1B, potentially leading to better cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that specifically target cancer cells while minimizing effects on healthy cells.
How similar studies have gone: Previous studies have shown promise in targeting oxidized forms of proteins for therapeutic purposes, indicating that this approach may be viable.
Where this research is happening
-
Florida Atlantic University
Boca Raton, United States Active
Researchers
- Principal investigator: Carroll, Kate Suzanne — Florida Atlantic University
- Study coordinator: Carroll, Kate Suzanne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.